Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

PURPOSE Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II trial evaluated two different immunostimulants combined with the MAGE-A3 protein to investigate whether a more robust and persistent immune response could be associated with increased clinical benefit. PATIENTS AND METHODS Patients with MAGE-A3-positive stage III or IV M1a melanoma were randomly assigned to receive the MAGE-A3 protein combined either with AS02B or with AS15 immunostimulant. Clinical end points were toxicity and rates of objective clinical responses, progression-free survival (PFS), and overall survival (OS). RESULTS Seventy-five patients were treated, with 36 eligible patients per arm. Both treatments were well tolerated. In the AS15 arm, four objective responses were observed (three complete responses and one partial response) versus one partial response in the AS02B arm. In the AS15 and AS02B arms, the PFS rates after 6 months were 25% and 14%, respectively; and the median OS times were 33 months and 19.9 months, respectively, with a median observation period of 48 months. Antibodies against MAGE-A3, found in all patients, showed three-fold higher titers in the AS15 arm. The anti-MAGE-A3 cellular response was also more pronounced in the AS15 arm. CONCLUSION In the MAGE-A3+AS15 arm, clinical activity was higher and the immune response more robust. Therefore, the AS15 immunostimulant was selected for combination with the MAGE-A3 protein in phase III trials.

[1]  T. Treasure,et al.  Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Bart Spiessens,et al.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Coulie,et al.  Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. , 2011, Cancer research.

[4]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[5]  C. Cluff.  Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. , 2010, Advances in experimental medicine and biology.

[6]  N. Altorki,et al.  MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized , 2009 .

[7]  Jeffrey Weber,et al.  Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). , 2008, The oncologist.

[8]  C. Bokemeyer,et al.  Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.

[9]  P. Lorigan,et al.  Does adjuvant vaccine therapy really have activity in malignant melanoma? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Socinski,et al.  Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Kirkwood,et al.  Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials , 2007 .

[12]  J. Jassem,et al.  Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) , 2007 .

[13]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[14]  C. Garbe,et al.  Diagnosis and treatment of cutaneous melanoma: state of the art 2006. , 2007, Melanoma research.

[15]  L. Liau,et al.  NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain1 , 2006, The Journal of Immunology.

[16]  V. Reuter,et al.  Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma , 2006, Clinical Cancer Research.

[17]  D. McCready,et al.  Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma , 2006, Cancer.

[18]  V. Paunescu,et al.  Monoclonal Antibodies Targeted Against Melanoma and Ovarian Tumors Enhance Dendritic Cell-Mediated Cross-Presentation of Tumor-Associated Antigens and Efficiently Cross-Prime CD8+ T Cells , 2006, Journal of immunotherapy.

[19]  A. Eggermont,et al.  Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma , 2005, International journal of cancer.

[20]  A. Simpson,et al.  Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[21]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[22]  Pierre van der Bruggen,et al.  Structure, chromosomal localization, and expression of 12 genes of the MAGE family , 2005, Immunogenetics.

[23]  S. Vuk-Pavlović,et al.  Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial , 2004, The Prostate.

[24]  C. Lamers,et al.  Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors , 2004, Journal of immunotherapy.

[25]  Yao-Tseng Chen,et al.  Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 , 2004, The Journal of Immunology.

[26]  G. Schuler,et al.  MAGE-A3 is a frequent tumor antigen of metastasized melanoma , 2004, Archives of Dermatological Research.

[27]  S. Aamdal,et al.  Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.

[28]  G. Sauter,et al.  Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen Expression: Potential Indications for Specific Immunotherapy and Prognostic Relevance in Squamous Cell Lung Carcinoma , 2002, Annals of surgery.

[29]  Yao-Tseng Chen,et al.  Expression of cancer-testis genes in human hepatocellular carcinomas. , 2002, Cancer immunity.

[30]  F. Marincola,et al.  Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading , 2001, International journal of cancer.

[31]  Yao-Tseng Chen,et al.  Expression of MAGE‐antigens in normal tissues and cancer , 2000, International journal of cancer.

[32]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[33]  E. Celis,et al.  A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. , 1999, Journal of immunotherapy.

[34]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[35]  P. Coulie,et al.  Estimation of the frequencies of anti‐MAGE‐3 cytolytic T‐lymphocyte precursors in blood from individuals without cancer , 1998, International journal of cancer.

[36]  P. Bruggen,et al.  T cell defined tumor antigens , 1997 .

[37]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[38]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[39]  J. Patard,et al.  Expression of mage genes in transitional‐cell carcinomas of the urinary bladder , 1995, International journal of cancer.